Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: A pilot study

Francesco Nicita, Alberto Spalice, Laura Papetti, Marina Nikanorova, Paola Iannetti, Pasquale Parisi

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Purpose Verapamil, a voltage-gated calcium channel blocker, has been occasionally reported to have some effect on reducing seizure frequency in drug-resistant epilepsy or status epilepticus. We aimed to investigate the efficacy of verapamil as add-on treatment in children with drug-resistant epilepsy. Methods Seven children with drug-resistant structural-metabolic, unknown or genetic (e.g., Dravet syndrome [DS]) epilepsy received verapamil as an add-on drug to baseline antiepileptic therapy. Verapamil was slowly introduced at the dosage of 1 mg/kg/day and titrated up to 1.5 mg/kg/day. After completing the titration period, patients entered a 14-month maintenance period and were followed up at 3, 8, and 14 months. Heart monitoring was performed at baseline and at each follow-up. The primary outcome measure was the response of seizures to verapamil. Results Three subjects with genetically determined DS showed a partial (reduction of 50-99%) response for all types of seizures. A patient with DS without known mutation showed a partial control of all types of seizures in the first 13 months; then seizures worsened and verapamil was suspended. Two patients with structural epilepsy and one with Lennox-Gastaut syndrome showed no improvement. Any side effects were recorded. Conclusions Add-on treatment with verapamil seems to have some effect in controlling seizures in patients with genetically determined DS. Our observations justify further research on the relationship between calcium channels, calcium channel blockers, and channelopathies.

Original languageEnglish
Pages (from-to)36-40
Number of pages5
JournalSeizure
Volume23
Issue number1
DOIs
Publication statusPublished - Jan 2014

Fingerprint

Verapamil
Myoclonic Epilepsy
Seizures
Calcium Channel Blockers
Therapeutics
Epilepsy
Channelopathies
Status Epilepticus
Calcium Channels
Drug Resistant Epilepsy
Pharmaceutical Preparations
Anticonvulsants
Maintenance
Outcome Assessment (Health Care)
Mutation
Research

Keywords

  • Blood-brain barrier
  • Dravet syndrome
  • Drug-resistance
  • Epilepsy
  • Multidrug transporters
  • P-glycoprotein
  • SCN1A
  • SMEI
  • Verapamil

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy : A pilot study. / Nicita, Francesco; Spalice, Alberto; Papetti, Laura; Nikanorova, Marina; Iannetti, Paola; Parisi, Pasquale.

In: Seizure, Vol. 23, No. 1, 01.2014, p. 36-40.

Research output: Contribution to journalArticle

Nicita, Francesco ; Spalice, Alberto ; Papetti, Laura ; Nikanorova, Marina ; Iannetti, Paola ; Parisi, Pasquale. / Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy : A pilot study. In: Seizure. 2014 ; Vol. 23, No. 1. pp. 36-40.
@article{ba587d20b52f464eb50a06a5e26f4aeb,
title = "Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: A pilot study",
abstract = "Purpose Verapamil, a voltage-gated calcium channel blocker, has been occasionally reported to have some effect on reducing seizure frequency in drug-resistant epilepsy or status epilepticus. We aimed to investigate the efficacy of verapamil as add-on treatment in children with drug-resistant epilepsy. Methods Seven children with drug-resistant structural-metabolic, unknown or genetic (e.g., Dravet syndrome [DS]) epilepsy received verapamil as an add-on drug to baseline antiepileptic therapy. Verapamil was slowly introduced at the dosage of 1 mg/kg/day and titrated up to 1.5 mg/kg/day. After completing the titration period, patients entered a 14-month maintenance period and were followed up at 3, 8, and 14 months. Heart monitoring was performed at baseline and at each follow-up. The primary outcome measure was the response of seizures to verapamil. Results Three subjects with genetically determined DS showed a partial (reduction of 50-99{\%}) response for all types of seizures. A patient with DS without known mutation showed a partial control of all types of seizures in the first 13 months; then seizures worsened and verapamil was suspended. Two patients with structural epilepsy and one with Lennox-Gastaut syndrome showed no improvement. Any side effects were recorded. Conclusions Add-on treatment with verapamil seems to have some effect in controlling seizures in patients with genetically determined DS. Our observations justify further research on the relationship between calcium channels, calcium channel blockers, and channelopathies.",
keywords = "Blood-brain barrier, Dravet syndrome, Drug-resistance, Epilepsy, Multidrug transporters, P-glycoprotein, SCN1A, SMEI, Verapamil",
author = "Francesco Nicita and Alberto Spalice and Laura Papetti and Marina Nikanorova and Paola Iannetti and Pasquale Parisi",
year = "2014",
month = "1",
doi = "10.1016/j.seizure.2013.09.009",
language = "English",
volume = "23",
pages = "36--40",
journal = "Seizure : the journal of the British Epilepsy Association",
issn = "1059-1311",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy

T2 - A pilot study

AU - Nicita, Francesco

AU - Spalice, Alberto

AU - Papetti, Laura

AU - Nikanorova, Marina

AU - Iannetti, Paola

AU - Parisi, Pasquale

PY - 2014/1

Y1 - 2014/1

N2 - Purpose Verapamil, a voltage-gated calcium channel blocker, has been occasionally reported to have some effect on reducing seizure frequency in drug-resistant epilepsy or status epilepticus. We aimed to investigate the efficacy of verapamil as add-on treatment in children with drug-resistant epilepsy. Methods Seven children with drug-resistant structural-metabolic, unknown or genetic (e.g., Dravet syndrome [DS]) epilepsy received verapamil as an add-on drug to baseline antiepileptic therapy. Verapamil was slowly introduced at the dosage of 1 mg/kg/day and titrated up to 1.5 mg/kg/day. After completing the titration period, patients entered a 14-month maintenance period and were followed up at 3, 8, and 14 months. Heart monitoring was performed at baseline and at each follow-up. The primary outcome measure was the response of seizures to verapamil. Results Three subjects with genetically determined DS showed a partial (reduction of 50-99%) response for all types of seizures. A patient with DS without known mutation showed a partial control of all types of seizures in the first 13 months; then seizures worsened and verapamil was suspended. Two patients with structural epilepsy and one with Lennox-Gastaut syndrome showed no improvement. Any side effects were recorded. Conclusions Add-on treatment with verapamil seems to have some effect in controlling seizures in patients with genetically determined DS. Our observations justify further research on the relationship between calcium channels, calcium channel blockers, and channelopathies.

AB - Purpose Verapamil, a voltage-gated calcium channel blocker, has been occasionally reported to have some effect on reducing seizure frequency in drug-resistant epilepsy or status epilepticus. We aimed to investigate the efficacy of verapamil as add-on treatment in children with drug-resistant epilepsy. Methods Seven children with drug-resistant structural-metabolic, unknown or genetic (e.g., Dravet syndrome [DS]) epilepsy received verapamil as an add-on drug to baseline antiepileptic therapy. Verapamil was slowly introduced at the dosage of 1 mg/kg/day and titrated up to 1.5 mg/kg/day. After completing the titration period, patients entered a 14-month maintenance period and were followed up at 3, 8, and 14 months. Heart monitoring was performed at baseline and at each follow-up. The primary outcome measure was the response of seizures to verapamil. Results Three subjects with genetically determined DS showed a partial (reduction of 50-99%) response for all types of seizures. A patient with DS without known mutation showed a partial control of all types of seizures in the first 13 months; then seizures worsened and verapamil was suspended. Two patients with structural epilepsy and one with Lennox-Gastaut syndrome showed no improvement. Any side effects were recorded. Conclusions Add-on treatment with verapamil seems to have some effect in controlling seizures in patients with genetically determined DS. Our observations justify further research on the relationship between calcium channels, calcium channel blockers, and channelopathies.

KW - Blood-brain barrier

KW - Dravet syndrome

KW - Drug-resistance

KW - Epilepsy

KW - Multidrug transporters

KW - P-glycoprotein

KW - SCN1A

KW - SMEI

KW - Verapamil

UR - http://www.scopus.com/inward/record.url?scp=84891160650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891160650&partnerID=8YFLogxK

U2 - 10.1016/j.seizure.2013.09.009

DO - 10.1016/j.seizure.2013.09.009

M3 - Article

C2 - 24113539

AN - SCOPUS:84891160650

VL - 23

SP - 36

EP - 40

JO - Seizure : the journal of the British Epilepsy Association

JF - Seizure : the journal of the British Epilepsy Association

SN - 1059-1311

IS - 1

ER -